Brazil’s Eurofarma Teams With Japan’s Eisai to Bring the Insomnia Drug Dayvigo to Market
Eurofarma has partnered with Japan's Eisai to sell the insomnia drug lemborexant (Dayvigo) in Brazil, targeting a market worth about US$240 million a year. The post Brazil’s Eurofarma Teams With Japan’s Eisai to Bring the Insomnia Drug Dayvigo to Market appeared first on The Rio Times .
Brazil's leading pharmaceutical company, Eurofarma, has partnered with Japanese firm Eisai to bring the insomnia drug Dayvigo to the Brazilian market. Dayvigo, also known as lemborexant, is a novel sleeping pill that targets the brain's wake system by blocking orexin, a chemical that keeps people alert. This approach differs from traditional sleeping pills, which broadly sedate the brain and can lead to dependence and grogginess.
Anvisa, Brazil's health regulator, has already registered Dayvigo for sale, but the drug is not yet available on pharmacy shelves. Before it can be sold, Brazil's CMED price board must set a maximum price. Eurofarma, based in São Paulo and one of Brazil's largest drugmakers, will handle the sales, leveraging its extensive pharmacy network across Latin America.
Eisai, a Japanese pharmaceutical company, developed lemborexant, and the two companies have worked together before, such as on the anti-obesity drug lorcaserin. The deal reflects the growing market for insomnia treatments in Brazil, which is valued at around US$240 million annually.
Written by urgent.news from The Rio Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
